MICHAEL REED FRANCIS, D.O.
Osteopathic Medicine at 500, Logan, UT
License number
Utah 7314857-1204
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
1350 N 500 E, Logan, UT 84341
PO Box 27128, Salt Lake City, UT 84127
PO Box 27128, Salt Lake City, UT 84127
Phone
(435) 792-1780
(435) 792-1647 (Fax)
(435) 792-1647 (Fax)
Personal information
See more information about MICHAEL REED FRANCIS at radaris.comName
Address
Phone
505 E 2780 N, Provo, UT 84604
549 N 730 W, American Fork, UT 84003
Professional information
Senior Associate At Marcus &Amp; Millichap
Position:
Senior Associate at Marcus & Millichap
Location:
Greater Salt Lake City Area
Industry:
Real Estate
Work:
Marcus & Millichap
-
Senior Associate
Dr. Michael R Francis, Logan UT - DO (Doctor of Osteopathic Medicine)
Specialties:
Internal Medicine
Address:
Intermountain Budge Clinic
1350 N 500 E, Logan 84341
(435) 752-0422 (Phone)
1350 N 500 E, Logan 84341
(435) 752-0422 (Phone)
Certifications:
Internal Medicine, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Intermountain Budge Clinic
1350 N 500 E, Logan 84341
Cache Valley Speciality Hospital
2380 North 400 East, North Logan 84341
Logan Regional Hospital
1400 North 500 East, Logan 84341
1350 N 500 E, Logan 84341
Cache Valley Speciality Hospital
2380 North 400 East, North Logan 84341
Logan Regional Hospital
1400 North 500 East, Logan 84341
Education:
Medical School
Kirksville College of Osteopathic Medicine
Graduated: 2007
Kirksville College of Osteopathic Medicine
Graduated: 2007
Michael Reed Francis, Logan UT
Specialties:
Internist
Address:
1350 N 500 E, Logan, UT 84341
Education:
Doctor of Osteopathy
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Compositions And Methods For Selective Inhibition Of Nicotine Acetylcholine Receptors
US Patent:
7531555, May 12, 2009
Filed:
Sep 30, 2004
Appl. No.:
10/956957
Inventors:
Roger L. Papke - Gainesville FL, US
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR
Assignee:
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
A61K 31/445, C07D 211/40
US Classification:
514327, 546242
Abstract:
The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.
Compositions And Methods For Selective Inhibition Of Nicotine Acetylcholine Receptors
US Patent:
2012032, Dec 27, 2012
Filed:
Jun 18, 2012
Appl. No.:
13/526076
Inventors:
ROGER L. PAPKE - Gainesville FL, US
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR
Assignee:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. - Gainesville FL
International Classification:
A61K 31/4465, A61K 31/4515, A61K 31/454, A61P 25/14, A61K 31/55, A61P 25/34, A61P 25/00, C07D 211/46, C12N 5/071
US Classification:
514217, 546242, 514315, 514327, 514322, 435375
Abstract:
The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.
Compositions And Methods For Selective Inhibition Of Nicotine Acetylcholine Receptors
US Patent:
2009006, Mar 5, 2009
Filed:
Nov 4, 2008
Appl. No.:
12/264768
Inventors:
Roger L. Papke - Gainesville FL, US
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR
International Classification:
A61K 31/4465, C07D 211/44, C07K 14/705
US Classification:
514315, 546242, 530409
Abstract:
The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.